NCT03269773 - Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD) | Biotech Hunter

Enrollment

197

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

March 30, 2019

Study Completion Date

June 20, 2019

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL

FURESTEM-AD Inj.

"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"

OTHER

Placebo

0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)

Trial Locations (11)

Unknown

Pusan National University Hospital, Busan

Chonnam National University Hospital, Gwangju

Dongguk University Medical Center, Ilsan

Gachon University Gil Medical Center, Incheon

Asan Medical Center, Seoul

Chung-Ang University Healthcare System, Seoul

Hanyang University Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Ajou University Hospital, Suwon

137-701

Catholic Medical Center, Seoul

All Listed Sponsors

lead

Kang Stem Biotech Co., Ltd.

INDUSTRY